Biotech Showcase™ 2019: Targeting tau to tackle neurodegenerative diseases
Without adequate treatments, neurodegenerative diseases such as Alzheimer’s and Parkinson’s remain an important unmet medical burden for aging societies. In a discussion at the 2019 Biotech Showcase, Asceneuron CEO Dirk Beher tells Mike Ward about the progress that the 2012 startup is making with its small-molecule therapeutics that reduce the accumulation of toxic aggregates of the tau protein into the neurofibrillary tangles that are widely recognized as the main cause of neurodegeneration and clinical symptoms in the majority of dementia cases, including Alzheimer’s disease.
Biotech Showcase™ 2019: F2G accelerates Phase IIb program vs life-threatening fungal infections
With no new antifungal agents for 15 years, immunocompromised patients are at risk from life-threatening infections. Ian Nicholson, CEO of F2G, updated Mike Ward during Biotech Showcase 2019 on the progress the biotech is having with its orotomide compound olorofim in a global open-label study for difficult-to-treat invasive fungal mold infections such as azole-resistant aspergillosis, scedosporiosis, lomentosporiosis, and other rare mold infections.